On the other hand, KRAS mutated NSCLC patients harboring mutations in the tumor suppressor genes STK11/LKB1 or CDKN2A show a worse prognosis than those with TP53 mutations [53]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.